ClinicalTrials.gg

Fatty Liver clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 663 studies for Fatty Liver across more than 10 countries. 185 are recruiting or about to start. 251 of them are mainly about Fatty Liver (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17. Counting its narrower condition Non-alcoholic Fatty Liver Disease too: 2,015 studies, 451 open.

ClinicalTrials.gov finds 2,251 studies for Fatty Liver. How that becomes 661 here

This page counts the studies the registry files under Fatty Liver, and those it files under no condition that list Fatty Liverthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

  1. 2,251Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −1,352Filed under a narrower condition, counted on its own pageNon-alcoholic Fatty Liver Disease 1,337
  3. −50List Fatty Liver as a condition, but the registry did not file them under itMost often written as “MASH - Metabolic Dysfunction-Associated Steatohepatitis” (8), “Metabolic Associated Fatty Liver Disease” (7), and “Metabolic Dysfunction-associated Fatty Liver Disease” (7). The registry filed them under other conditions only, most often Diabetes Mellitus, Type 2 (15) and Obesity (13).
  4. −188Match it another way124 name it in the title, 8 in a keyword, and 56 by a synonym or other text the search reads.
  5. 661The count on this page65 of them list Fatty Liver in their own words; the registry filed them under no condition.

Status

Completed
327
Recruiting
117
Status unknown
64
Not yet recruiting
55
Terminated
33
Active, not recruiting
31

Phase

Phase 2
110
Phase 1
54
Phase 4
43
Phase 3
33
Early Phase 1
8

Where

United States
211
China
63
France
44
United Kingdom
44
Canada
41
Italy
33

Who develops what

Add Fatty Liver to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 24 programs from 21 companies, 19 with this as their studies’ main aim; 5 with a live phase 3 study; 7 primary completions in the next 12 months. Compare Eli Lilly, Jiangsu HengRui Medicine and Arrowhead Pharmaceuticals here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

None given by two companies or more yet.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
pemvidutide☆ Track1 live phase-3 study: NCT07795164Altimmune, Inc.
efimosfermin alfa☆ Track2 live phase-3 studies: NCT07701993, NCT07704892GlaxoSmithKline

The 2 in phase 3 with the nearest primary completion, of 24 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (7)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Feb 2027 est.HU6, Dinifedriton · Rivus Pharmaceuticals, Inc. · Phase 2 main aimNCT07491458 A Trial to Investigate Safety, Exposure, and Efficacy of HU6 Compared With Placebo in Adult Participants With Metabolic Dysfunction-associated Steatohepatitis (MASH) — primary endpoint: Number and Percentage of Adverse Events (AEs) · 180 enrolled
  • 14 Feb 2027 est.tesamorelin · Hudson Biotech · Phase 2 named, not the main aimNCT07481734 Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease — primary endpoint: Change from baseline in hepatic fat fraction by MRI-PDFF (percentage points) · 120 enrolled
  • Jun 2027 est.QL2401 · Qilu Pharmaceutical Co., Ltd. · Phase 2 main aimNCT07620366 To Evaluate the Efficacy and Safety of QL2401 in Patients With Metabolic Dysfunction-associated Steatohepatitis and Liver Fibrosis — primary endpoint: Changes in liver fat content (%) measured by magnetic resonance imaging-proton density fat fraction (MRI-PDFF) at week 12 relative to baseline · 132 enrolled

4 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Fatty Liver studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here GLP-1 receptor agonists 4 open · SGLT2 inhibitors 2 open · Statins 4

Coming up

58studies finish main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest

Who these studies take

Of the 117 Fatty Liver studies recruiting now, 35 (30%) set no upper age limit and 63 (54%) stop at 75 or younger. 8 (7%) take children under 18. 2 (2%) are for women only and 1 (1%) for men only; 32 (27%) take healthy volunteers.

Recruiting studies that take each age, of 117
AgeWomenMen
106 (5%)5 (4%)
1898 (84%)97 (83%)
30109 (93%)108 (92%)
40110 (94%)109 (93%)
50109 (93%)108 (92%)
65100 (85%)99 (85%)
7573 (62%)72 (62%)
8544 (38%)42 (36%)

Across all 663 studies, recruiting or not: 54% stop at 75 or younger and 29% at 65; 12% take children; 4% are for women only and 4% for men only; 27% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Fatty Liver studies take

Of 41 phase 2 interventional studies under Fatty Liver, half reached primary completion within 24 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 133 mo8–47 · 22 studies——
Phase 224 mo16–36 · 41 studies——
Interventional, no phase21 mo10–39 · 145 studies—21 mo10–40 · 136 studies
Observational33 mo20–68 · 96 studies—35 mo21–68 · 87 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 663. Browse all 663 → or search them.